Abstract
Lipid-lowering therapy is used to reduce the risk of atherosclerotic cardiovascular disease (ASCVD), with statins being the drugs of choice. Despite the use of statins, the risk of additional cardiovascular events persists. Based on lipid levels and estimates of ASCVD risk, statins are used in combination with other lipid-lowering therapies, such as ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and eicosapentaenoic acid–only omega-3 fatty acids. Overall, combinations of fenofibrate or niacin with a statin have failed to reduce ASCVD risk. Potentially effective drugs with novel lipid-lowering mechanisms are currently being investigated in clinical trials for use in patients with ASCVD or familial hypercholesterolemia.